ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

apixaban

Also written as “Apixaban”, “Apixaban 5 MG” and “Apixaban 5 mg Oral Tablet”.

Its studies are mostly in Venous Thrombosis · Atrial Fibrillation · Thrombosis · Acute Coronary Syndrome · Venous Thromboembolism, led by 7 companies.

Drug pageApixaban: every studyMany companies study it; this page follows only the 37 they lead. All 179 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 6, 201337 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb260 open or runningphase 4since Jun 6, 2013Nov 22, 2004none ahead
Pfizerits history only60 open or runningphase 4since Feb 5, 2014Nov 5, 2008none ahead
Artivionits history only10 open or runningphase 3since Oct 9, 2019Oct 9, 2019none ahead
Dexa Medica Groupits history only10 open or runningphase 1since Feb 5, 2025Feb 5, 2025none ahead
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Sep 4, 2023Sep 4, 2023none ahead
Scotmann Pharmaceuticalsits history only10 open or runningphase 2since Oct 21, 2021Oct 21, 2021none ahead
TAHO Pharmaceuticalsits history only10 open or runningearly phase 1since Jul 24, 2023Jul 24, 2023none ahead

Also a collaborator on its studies: Link Medical Research AB, Parexel and PT Equilab International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Nov 22, 2004.

  1. Mar 5, 20082 phase 3 studies in Venous ThrombosisNCT00633893, NCT00643201
  2. Jan 28, 2009Phase 3 study in Acute Coronary SyndromeNCT00831441 · 7,484 enrolled · United States, Argentina, Australia and more
  3. Sep 3, 2010Phase 1 study in Venous ThromboembolismNCT01195727 · 13 enrolled · United States, Belgium, Canada and more
  4. Apr 21, 2011Phase 1 study in Kidney Failure, ChronicNCT01340586 · 18 enrolled · United States
  5. Oct 12, 2012Phase 1 study in ThromboembolismNCT01707394 · 49 enrolled · United States, Australia, Canada and more
  6. Jun 6, 20132 phase 4 studiesNCT01884337, NCT01884350
  7. Jan 10, 20143 phase 1 studiesNCT02034591, NCT02034578, NCT02034565
  8. Mar 28, 2014Phase 1 study in ThrombosisNCT02101112 · 69 enrolled
  9. Oct 9, 20142 phase 1 studies in N/A - Healthy SubjectsNCT02262533, NCT02262520
  10. Jan 21, 2015Phase 3 study in LymphomaNCT02369653 · 512 enrolled · United States, Australia, Belgium and more
  11. Apr 9, 2015Phase 4 study in Acute Coronary SyndromeNCT02415400 · 4,614 enrolled · United States, Argentina, Australia and more
  12. May 26, 2015Phase 4 study in Venous ThromboembolismNCT02464969 · 229 enrolled · United States, Australia, Austria and more
  13. Sep 19, 2016Phase 1 study in Venous ThromboembolismNCT02912234 · 20 enrolled · United States
  14. Nov 18, 2016Phase 2 study in ThrombosisNCT02981472 · 192 enrolled · United States, Argentina, Australia and more

TargetBeta

F10 →read by rule
“Coagulation factor X inhibitor”ChEMBL 37, by rule

Other programs on F10

ProgramCompanyFurthest phaseStudies
RivaroxabanruleBayerphase 477
emicizumabruleHoffmann-La Rochephase 413
Factor Xrulekedrion-s-p-aphase 31

Studies

All 26 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02981472Thrombosis · United States, Argentina, Australia and more2CompletedOct 18, 2021192
NCT02912234Venous Thromboembolism · United States1CompletedOct 201620
NCT02464969Venous Thromboembolism · United States, Australia, Austria and more4CompletedApr 30, 2024229
NCT02415400Acute Coronary Syndrome · United States, Argentina, Australia and more4CompletedNov 10, 20184,614
NCT02369653Lymphoma · United States, Australia, Belgium and more3CompletedJul 7, 2021512
NCT02262533N/A - Healthy Subjects · United States1CompletedJun 200715
NCT02262520N/A - Healthy Subjects1CompletedMar 200624
NCT02101112Thrombosis1CompletedMay 201469
NCT02034591Healthy Subjects · United States1CompletedNov 201137
NCT02034578Healthy Volunteers · United States1CompletedAug 201175
NCT02034565Healthy Volunteers · United States1CompletedMar 201048
NCT01884350Non-valvular Atrial Fibrillation · Belgium, France, Germany and more4CompletedJan 20, 20161,217
NCT01884337Anticoagulation · India4CompletedJun 4, 2018557
NCT01707394Thromboembolism · United States, Australia, Canada and more1CompletedJun 30, 202049
NCT01340586Kidney Failure, Chronic · United States1CompletedSep 201118
NCT01195727Venous Thromboembolism · United States, Belgium, Canada and more1TerminatedJun 14, 201213
NCT00831441Acute Coronary Syndrome · United States, Argentina, Australia and more3TerminatedMar 20117,484
NCT00643201Venous Thrombosis · United States, Argentina, Australia and more3CompletedMar 20135,614
NCT00633893Venous Thrombosis · United States, Argentina, Australia and more3CompletedAug 20122,711
NCT00496769Atrial Fibrillation · United States, Argentina, Australia and more3CompletedNov 30, 20106,421
NCT00457002Venous Thrombosis · United States, Argentina, Australia and more3CompletedMay 20116,758
NCT00452530Venous Thrombosis · Austria, Belgium, Brazil and more3CompletedJan 20093,221
NCT00412984Atrial Fibrillation · United States, Argentina, Australia and more3CompletedMay 25, 201120,976
NCT00313300Acute Coronary Syndrome · United States, Austria, Belgium and more2CompletedMay 20081,741
NCT00252005Venous Thrombosis · United States, Australia, Austria and more2CompletedFeb 2007520
NCT00097357Venous Thrombosis · United States, Argentina, Australia and more3CompletedDec 20051,238

How it is read

Names in the registry

  • “Apixaban”, 38 entries
  • “Apixaban 5 MG”, 2 entries
  • “apixaban”, 2 entries
  • “Apixaban 5 mg Oral Tablet”, 1 entry
  • “Apixaban 5MG”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.